Bristol-Myers Squibb (BMY) announced results for its combination treatment treating patients with metastatic renal cell carcinoma (kidney cancer). The company reported mixed results in after-hours trade on Tuesday sending the stock lower by 2.4%. The company reported that it met one of three primary endpoints of the study. It plans to continue the trial to completion and the trend for overall survival (OS) will be determined at that time. In my opinion, it is not the end for the combination of Opdivo and Yervoy in the metastatic renal cell carcinoma indication. That is because the company showed that the overall response rate (ORR) was stronger in the combination treatment group compared to the sunitinib group. Sunitinib is marketed by Pfizer (PFE) under the name of Sutent.
